Aeterna Zentaris Inc. (AEZS)
Symbol Info
Listed Symbol AEZS
Name Aeterna Zentaris Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $26,881,000
Latest Fiscal EPS $0.25
Price Info
21 Day Moving Average $1.0253
21 Day EMA $1.107790
50 Day Moving Average $1.5973
50 Day EMA $1.516830
200 Day EMA $2.429420
200 Day Moving Average 3.025530
52 Week High $5.57
52 Week Low $0.81
52 Week Change $-23.021599
Alpha -0.032256
Beta 1.1109
Standard Deviation 0.322988
R2 0.013953
Periods 60
Share Information
10 Day Average Volume 180,515
20 Day Average Volume 217,032
30 Day Average Volume 212,745
50 Day Average Volume 166,327
Outstanding Shares 19,882,410
Float Shares 19,882,410
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 48
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 27,870
Institute Holdings Percent 8.100000
Institute Sold Previous 3 Months 453,799
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $0.1676000
7 Day Percent Change 18.57%
21 Day Price Change $0.0740001
21 Day Percent Change 7.43%
30 Day Price Change $-0.5647999
30 Day Percent Change -34.55%
Month To Date Price Change $0.0400
Month To Date Percent 3.88%
90 Day Price Change $-1.47
90 Day Percent Change -57.87%
Quarter To Date $0.040000
Quarter To Date Percent 3.88%
180 Day Price Change $-3.18
180 Day Percent Change -74.82%
200 Day Price Change $-4.03
200 Day Percent Change -79.02%
Year To Date $-1.87
Year To Date Percent -63.61%
Profile
Description AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.
Details
Issue Type CS
Market Cap $21,274,179
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 19,954,290
CEO Michael Ward
Employees 22
Last Audit UQ
Classification
CIK 0001113423
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 315 Sigma Drive
Suite 302D
Summerville, SC 29486
Website https://www.zentaris.com
Facisimile
Telephone +1 843 900-3201
Email IR@aezsinc.com
Key Ratios
Profitability
EBIT Margin -497.8
EBITDA Margin -490.9
Pre-Tax Profit Margin -33,870.6
Profit Margin Cont -
Gross Margin 12.20
Profit Margin TOT -
Income Statements
Revenue $1,623,000
Revenue Per Share $0.1929
Revenue 3 Years $121.93
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $12,323,388
Price To Sales 5.545801
Price To Free Cash -2.7
PE High Last 5 Years -
Price To Book 34.1
Price To Cash Flow 9.9
PE Low Last 5 Years -
Price To Tangible Book -1.8
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 1.7
Leverage Ratio -3.3
Quick Ratio 1.4
Long Term Debt To Capital -
Assets
Receivables Turnover 1.6
Invoice Turnover 1.90
Assets Turnover -
Management Effectiveness
Return Assets -47.11
Return On Equity -380.75
Return On Capital -280.46
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AEZS
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.